These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7895463)

  • 21. Evaluation approach can significantly influence oral glucose-lowering drugs total mortality risks in retrospective cohorts of type 2 diabetes mellitus patients.
    Khalangot M; Kovtun V
    Curr Diabetes Rev; 2014; 10(5):336-42. PubMed ID: 25336066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the antioxidant and vascular effects of gliclazide and glibenclamide in Type 2 diabetic patients: a randomized crossover study.
    Shimabukuro M; Higa N; Takasu N
    J Diabetes Complications; 2006; 20(3):179-83. PubMed ID: 16632238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gliclazide mainly affects insulin secretion in second phase of type 2 diabetes mellitus.
    Ligtenberg JJ; Reitsma WD; van Haeften TW
    Horm Metab Res; 2001 Jun; 33(6):361-4. PubMed ID: 11456286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of gliclazide and left ventricular mass in type 2 diabetic patients.
    Pan NH; Lee TM; Lin MS; Huang CL; Chang NC
    Diabetes Res Clin Pract; 2006 Nov; 74(2):121-8. PubMed ID: 16631274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glimepiride: new preparation. Just another hypoglycaemic sulphonylurea agent.
    Prescrire Int; 1998 Aug; 7(36):106-7. PubMed ID: 10342947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population.
    Juurlink DN; Gomes T; Shah BR; Mamdani MM
    Diabet Med; 2012 Dec; 29(12):1524-8. PubMed ID: 22913620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation.
    Abbink EJ; van der Wal PS; Sweep CG; Smits P; Tack CJ
    Diabetes Metab Res Rev; 2004; 20(6):466-71. PubMed ID: 15386823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.
    Bo S; Castiglione A; Ghigo E; Gentile L; Durazzo M; Cavallo-Perin P; Ciccone G
    Eur J Endocrinol; 2013 Jul; 169(1):117-26. PubMed ID: 23660643
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preventive and therapeutic effects of gliclazide on diabetic retinopathy: comparison with glibenclamide treatment.
    Minami N; Ikeda Y; Abe M
    Tohoku J Exp Med; 1983 Dec; 141 Suppl():707-11. PubMed ID: 6440314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia.
    Rosak C; Haupt E; Walter T; Werner J
    Diabetes Nutr Metab; 2002 Jun; 15(3):143-51. PubMed ID: 12173728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic cause of hyperglycaemia and response to treatment in diabetes.
    Pearson ER; Starkey BJ; Powell RJ; Gribble FM; Clark PM; Hattersley AT
    Lancet; 2003 Oct; 362(9392):1275-81. PubMed ID: 14575972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Free radical scavenging activity of sulfonylureas: a clinical assessment of the effect of gliclazide.
    Jennings PE; Belch JJ
    Metabolism; 2000 Feb; 49(2 Suppl 1):23-6. PubMed ID: 10693916
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of sulphonylureas in the elderly.
    Graal MB; Wolffenbuttel BH
    Drugs Aging; 1999 Dec; 15(6):471-81. PubMed ID: 10641958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How does glibenclamide lower plasma glucose concentration in patients with type 2 diabetes?
    Jeng CY; Hollenbeck CB; Wu MS; Chen YD; Reaven GM
    Diabet Med; 1989; 6(4):303-8. PubMed ID: 2524334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3.
    Tuomi T; Honkanen EH; Isomaa B; Sarelin L; Groop LC
    Diabetes Care; 2006 Feb; 29(2):189-94. PubMed ID: 16443858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Forearm vascular reactivity is differentially influenced by gliclazide and glibenclamide in chronically treated type 2 diabetic patients.
    Wascher TC; Boes U
    Clin Physiol Funct Imaging; 2005 Jan; 25(1):40-6. PubMed ID: 15659079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
    van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
    Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative study of the therapeutic effects of glibenclamide or the fixed combination of glibenclamide-phenformin with those of gliclazide or chlorpropamide.
    Raptis AE; Tountas N; Yalouris AG; Hadjidakis D; Zaharis A; Miras K; Raptis SA
    Acta Diabetol Lat; 1990; 27(1):11-22. PubMed ID: 2110711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diabetic endothelial dysfunction: effect of free radical scavenging in Type 2 diabetic patients.
    De Mattia G; Laurenti O; Fava D
    J Diabetes Complications; 2003; 17(2 Suppl):30-5. PubMed ID: 12623166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.